Remarks

• See Section 6 regarding identifying patients at low risk.
• The marginal benefits of nirmatrelvir-ritonavir for patients at low risk of hospitalization (those expected to have a 0.5% risk of hospital admission) suggest most patients would not want to use this treatment, but a minority may still be inclined to do so.
• The GDG noted the uncertainty in baseline risk estimates and uncertainty and variability in patient values and preferences when deciding on a conditional recommendation, rather than a strong recommendation, against nirmatrelvir-ritonavir.
• Given considerations regarding resources and equity, the GDG concluded that health care systems may reasonably not offer this drug to patients at low risk of hospitalization.